Mercadolibre, Inc. Called a Great Growth Stock and Incyte Corporation Rockets on Positive Breakthrough Data Results
NEW YORK, NY / ACCESSWIRE / May 19, 2017 / It has been an impressive month for Mercadolibre, especially after releasing positive first quarter results almost two weeks ago. The stock has been considered a great growth stock. Incyte Corporation's shares blew up after the company reported breakthrough data that even a Goldman Sachs analyst referred to as "solid data."
RDI Initiates Coverage on:
Mercadolibre, Inc.
https://ub.rdinvesting.com/news/?ticker=MELI
Incyte Corporation
https://ub.rdinvesting.com/news/?ticker=INCY
Mercadolibre, Inc.'s shares closed down 2.78% on Thursday despite no significant news aside from a favorable and positive outlook on the stock from Zacks Equity Research. The company, which is known as the Amazon of Latin America, has been seeing some major gains after it released its first quarter results earlier this month. Mercadolibre reported that sales grew 74% year over year for the period to $273.9 million. Net income at $1.10 per share was a growth of 60% and came in significantly higher than what estimates had called for. Mercadolibre is an online trading company with focus on enabling e-commerce and its related services.
Access RDI's Mercadolibre Research Report at:
https://ub.rdinvesting.com/news/?ticker=MELI
Incyte Corporation's shares closed the day up 6.90% yesterday on volume nearly three times its usual volume. Shares exploded after never before seen data was revealed from two of the company's key clinical trials. Data reported from the biopharmaceutical company indicated that something that wasn't possible before could be possible now. Incyte has been developing a cancer immunotherapy called an IDO inhibitor. The drug maker's goal has been to use an IDO inhibitor with a PD-1 inhibitor in order to help people respond to cancer treatments better. This is compared to using just a PD-1 inhibitor. Goldman Sachs said in a note, "Solid data validates IDO as a leading IO add-on." This could be a breakthrough in medicine so no wonder traders reacted positively towards the news. Jefferies analyst Jeffrrey Holford also commented and said in a note, "INCY's IDO looks most promising in this class so far, but not very disruptive in relation to immuno-oncology as a whole."
Access RDI's Incyte Corporation Research Report at:
https://ub.rdinvesting.com/news/?ticker=INCY
Our Actionable Research on Mercadolibre, Inc. (NASDAQ: MELI) and Incyte Corporation (NASDAQ: INCY) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
